Works by MAHAFFEY, KENNETH W.
Results: 187
Acute Coronary Syndromes.
- Published in:
- Texas Heart Institute Journal, 2006, v. 33, n. 2, p. 187
- By:
- Publication type:
- Article
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
- Published in:
- Pharmaceutical Statistics, 2015, v. 14, n. 4, p. 368, doi. 10.1002/pst.1694
- By:
- Publication type:
- Article
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
- Published in:
- Pharmaceutical Statistics, 2015, v. 14, n. 3, p. 242, doi. 10.1002/pst.1680
- By:
- Publication type:
- Article
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
- Published in:
- Diabetes Care, 2024, v. 47, n. 3, p. 501, doi. 10.2337/dc23-1450
- By:
- Publication type:
- Article
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
- Published in:
- 2022
- By:
- Publication type:
- journal article
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium--Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 403, doi. 10.2337/dc14-1237
- By:
- Publication type:
- Article
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01832-5
- By:
- Publication type:
- Article
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01619-0
- By:
- Publication type:
- Article
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2018, v. 46, n. 4, p. 435, doi. 10.1007/s11239-018-1715-1
- By:
- Publication type:
- Article
The ARREST Pneumonia Clinical Trial. Rationale and Design.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Canagliflozin review – safety and efficacy profile in patients with T2DM.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2019, v. 12, p. 209, doi. 10.2147/DMSO.S184437
- By:
- Publication type:
- Article
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
- Published in:
- 2000
- By:
- Publication type:
- journal article
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2022, v. 27, n. 1, p. 21, doi. 10.1177/1358863X211038620
- By:
- Publication type:
- Article
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2021, v. 26, n. 6, p. 608, doi. 10.1177/1358863X211017641
- By:
- Publication type:
- Article
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
- Published in:
- Vascular Medicine, 2019, v. 24, n. 5, p. 422, doi. 10.1177/1358863X19864172
- By:
- Publication type:
- Article
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2018, v. 23, n. 6, p. 523, doi. 10.1177/1358863X18775594
- By:
- Publication type:
- Article
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial.
- Published in:
- JGIM: Journal of General Internal Medicine, 2008, v. 23, n. 3, p. 310, doi. 10.1007/s11606-007-0498-4
- By:
- Publication type:
- Article
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
- Published in:
- Cardiovascular Research, 2022, v. 118, n. 4, p. 1103, doi. 10.1093/cvr/cvab128
- By:
- Publication type:
- Article
The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
- Published in:
- Catheterization & Cardiovascular Interventions, 2007, v. 69, n. 1, p. 73, doi. 10.1002/ccd.20897
- By:
- Publication type:
- Article
Utilization of catheterization and revascularization procedures in patients with non‐ST segment elevation acute coronary syndrome over the last decade.
- Published in:
- Catheterization & Cardiovascular Interventions, 2005, v. 66, n. 2, p. 149, doi. 10.1002/ccd.20469
- By:
- Publication type:
- Article
Grade III Ischemia on Presentation with Acute Myocardial Infarction Predicts Rapid Progression of Necrosis and Less Myocardial Salvage with Thrombolysis.
- Published in:
- Cardiology, 2002, v. 97, n. 3, p. 166, doi. 10.1159/000063334
- By:
- Publication type:
- Article
The development of a mobile app‐focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials.
- Published in:
- Stat, 2022, v. 11, n. 1, p. 1, doi. 10.1002/sta4.470
- By:
- Publication type:
- Article
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3530, doi. 10.1111/dom.15685
- By:
- Publication type:
- Article
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3371, doi. 10.1111/dom.15678
- By:
- Publication type:
- Article
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 758, doi. 10.1111/dom.15340
- By:
- Publication type:
- Article
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091
- By:
- Publication type:
- Article
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2043, doi. 10.1111/dom.15065
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2038, doi. 10.1111/dom.15057
- By:
- Publication type:
- Article
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1413, doi. 10.1111/dom.14978
- By:
- Publication type:
- Article
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2459, doi. 10.1111/dom.14832
- By:
- Publication type:
- Article
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1927, doi. 10.1111/dom.14772
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1072, doi. 10.1111/dom.14671
- By:
- Publication type:
- Article
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 12, doi. 10.1111/dom.14539
- By:
- Publication type:
- Article
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2707, doi. 10.1111/dom.14525
- By:
- Publication type:
- Article
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1652, doi. 10.1111/dom.14386
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 382, doi. 10.1111/dom.14226
- By:
- Publication type:
- Article
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2199, doi. 10.1111/dom.14143
- By:
- Publication type:
- Article
Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, p. 46, doi. 10.1111/dom.13987
- By:
- Publication type:
- Article
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 530, doi. 10.1111/dom.13920
- By:
- Publication type:
- Article
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 926, doi. 10.1111/dom.12924
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal ( CANVAS-R): A randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 387, doi. 10.1111/dom.12829
- By:
- Publication type:
- Article
A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction.
- Published in:
- Advances in Medical Education & Practice, 2017, v. 8, p. 559, doi. 10.2147/AMEP.S138467
- By:
- Publication type:
- Article
Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Resting Heart Rate and Associations With Clinical Measures From the Project Baseline Health Study: Observational Study.
- Published in:
- Journal of Medical Internet Research, 2024, v. 26, p. 1, doi. 10.2196/60493
- By:
- Publication type:
- Article
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 48, p. 4891, doi. 10.1093/eurheartj/ehab497
- By:
- Publication type:
- Article